TaiMed Biologics (Taiwan) Today
TaiMed Biologics is selling for under 84.90 as of the 31st of January 2025; that is 0.7 percent down since the beginning of the trading day. The stock's lowest day price was 84.2. The performance scores are derived for the period starting the 1st of January 2025 and ending today, the 31st of January 2025. Click here to learn more.
Valuation
Check how we calculate scores
TaiMed Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. TaiMed Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding TaiMed Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | James Chang |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
TaiMed Biologics (4147) is traded on Taiwan OTC Exchange in Taiwan and employs 37 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 17.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate TaiMed Biologics's market, we take the total number of its shares issued and multiply it by TaiMed Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. TaiMed Biologics operates under Biotechnology sector and is part of Health Care industry. The entity has 252.37 M outstanding shares.
TaiMed Biologics has accumulated about 1.02 B in cash with (211.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03.
Check TaiMed Biologics Probability Of Bankruptcy
TaiMed Biologics Risk Profiles
Although TaiMed Biologics' alpha and beta are two of the key measurements used to evaluate TaiMed Biologics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.44 | |||
| Semi Deviation | 2.13 | |||
| Standard Deviation | 2.17 | |||
| Variance | 4.7 |
TaiMed Stock Against Markets
TaiMed Biologics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TaiMed Biologics stock to make a market-neutral strategy. Peer analysis of TaiMed Biologics could also be used in its relative valuation, which is a method of valuing TaiMed Biologics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
TaiMed Biologics Corporate Directors
| MingChing Chen | Independent Director | Profile | |
| LungYeh Cho | Director | Profile | |
| LuPing Chow | Director | Profile | |
| Howard Lee | Independent Director | Profile |
Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.